Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 2, 2008, Pages 173-178

  Atiemo, Andrew D ^a   Ng'Alla, Ladina S ^a   Vaidya, Dhananjay ^a   Williams, Marlene S ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Antiplatelet therapy; Aspirin nonresponse; Coronary artery disease; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; CELL PROTEIN; PROTEIN PAC 1; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORAX PAIN; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ANGINA, UNSTABLE; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS;

EID: 42549172230     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0045-5     Document Type: Article

References (26)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324(7329):71-86
2. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71(5):397-403
3. Buchanan MR, Brister SJ (1995) Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 11(3):221-227
4. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3):234S-264S
5. Williams MS, Kickler TS, Vaidya D, Ng'alla LS, Bush DE (2006) Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 21(3):241-247
6. Chen WH, Lee PY, Ng W, Tse HF, Lau CP (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43(6):1122-1126
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14):1650-1655
8. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961-965
9. Patrono C (2003) Aspirin resistance: Definition, mechanisms and clinical read-outs. J Thromb Haemost 1(8):1710-1713
10. Sanderson S, Emery J, Baglin T, Kinmonth AL (2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142(5):370-380
11. Mason PJ, Freedman JE, Jacobs AK (2004) Aspirin resistance: Current concepts. Rev Cardiovasc Med 5(3):156-163
12. Pamukcu B, Oflaz H, Oncul A et al (2006) The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 22(2):103-110
13. Pamukcu B, Oflaz H, Onur I et al (2007) Clinical relevance of aspirin resistance in patients with stable coronary artery disease: A prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 18(2):187-192
14. Gum PA, Kottke-Marchant K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88(3):230-235
15. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2006) Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 97(1):38-43
16. Frossard M, Fuchs I, Leitner JM et al (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110(11):1392-1397
17. Gianetti J, Parri MS, Sbrana S et al (2006) Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res 118(4):487-493
18. Cipollone F, Ciabattoni G, Patrignani P et al (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102(9):1007-1013
19. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87(23):9383-9387
20. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A (2001) Pl (A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104(22):2666-2672
21. Furman MI, Benoit SE, Barnard MR et al (1998) Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31(2):352-358
22. Chakroun T, Gerotziafas G, Robert F et al (2004) In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 124(1):80-85
23. Fressinaud E, Veyradier A, Truchaud F et al (1998) Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 91(4):1325-1331
24. Veyradier A, Fressinaud E, Boyer-Neumann C, Trossaert M, Meyer D (2000) von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost 84(4):727-728
25. Nitu-Whalley IC, Lee CA, Hermans C (2001) Reassessment of the correlation between the von Willebrand factor activity, the PFA-100, and the bleeding time in patients with von Willebrand disease. Thromb Haemost 86(2):715-716
26. Collet JP, Montalescot G, Vicaut E et al (2003) Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108(4):391-394